Business Wire

DC-XYLEM

22.4.2024 14:01:25 CEST | Business Wire | Press release

Share
Spanish and U.S. Companies Recognized for World-class Water Stewardship

Spanish water utility Consorci d'Aigües de Tarragona and Oklahoma-based Mingo Aerospace (a Sunvair Group Company) have been recognized as leaders in water stewardship by global water technology company, Xylem (NYSE: XYL).

Xylem’s Sustainability Excellence Awards celebrate companies using technologies in innovative ways to solve critical water challenges and advance sustainability. A sector leader in sustainability, Xylem is committed to helping customers and communities achieve their environmental goals.

Consorci d'Aigües de Tarragona (CAT), winner in the utility category, supplies water to 800,000 people and essential industries in Spain’s water-stressed Catalonia region. Following a major pipeline failure in 2020, the utility deployed a structural digital twin to provide live monitoring of its infrastructure. The technology streamlined CAT’s preventative maintenance and reduced its operational costs by €1 million. The transformative approach to asset management enabled CAT to minimize pipe breaks and leaks, lowering annual water use by more than 25,000 cubic meters (6.6 million gallons) – equivalent to more than 10 Olympic-sized swimming pools – and reducing energy use and emissions.

“The digital twin is helping improve service for our customers and supporting our sustainability goals. We have already prevented a pipe breakage that could have resulted in a 15-day outage for 800,000 people. By avoiding leaks and major outages, we minimize the risk of disruption to our community and businesses, while using less water and reducing emissions,” said Joan Alginet, President of CAT.

Mingo Aerospace, winner in the industrial category, implemented a closed-loop wastewater system to safely and efficiently manage wastewater used in aircraft component manufacturing. The system introduced by the Oklahoma-based aircraft repair and manufacturing company treats potentially hazardous process wastewater for reuse rather than discharging it, protecting local waterways, and reducing water use by 189 cubic meters (50,000 gallons) per year. The digitally monitored system has also simplified regulatory compliance for the company and the city related to time- and cost-intensive testing.

“With the closed-loop wastewater recycling system, we have reduced our reliance on freshwater sources and eliminated the need to discharge wastewater into local waterways. We have also simplified our operations because digital monitoring of the wastewater system reduces the requirement for day-to-day manual testing,” said Dale Roberts, President of Mingo Aerospace.

“Around the world, water managers are demonstrating their commitment to accelerating sustainability practices and recognizing technology’s role in helping them get there,” said Austin Alexander, Vice President of Sustainability and Social Impact at Xylem. “Pioneers like CAT and Mingo Aerospace set the standard for water stewardship with innovative technology strategies that enable their organizations to deliver business and sustainability wins, hand-in-hand.”

Held annually, the Sustainability Excellence Awards recognize customers for excellence in water stewardship. The Awards highlight customers for their use of new or existing technologies in innovative, sustainable ways, as well as customers who have made significant strides in water and energy efficiency.

About Xylem

Xylem (XYL) is a leading global water technology company committed to solving the world’s critical water challenges with innovation and expertise. Our 23,000 diverse employees delivered combined pro forma revenue of $8.1 billion in 2023. We are creating a more sustainable world by enabling our customers to optimize water and resource management and helping communities in more than 150 countries become water secure. Join us at www.xylem.com and Let’s Solve Water.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240422040628/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye